Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 6/20 | 0.46 |
| ▸ | RAB9A | P51151 | 6/20 | 0.46 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | PKM | P14618 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10902610 | 1.00 | MAPT (0.46) | MAPTNPC1RAB9APSMB8SMN1; SMN2 | |
| SCHEMBL8069919 | 0.85 | MAPT (0.46) | MAPTNPC1RAB9APSMB8SMN1; SMN2 | |
| SCHEMBL86097 | 0.84 | MAPT (0.48) | MAPTNPC1RAB9APSMB8SMN1; SMN2 | |
| SCHEMBL2147325 | 0.84 | MAPT (0.48) | MAPTNPC1RAB9APSMB8SMN1; SMN2 | |
| SCHEMBL8409764 | 0.81 | NPC1 (0.46) | MAPTNPC1RAB9APSMB8SMN1; SMN2 | |
| SCHEMBL12396620 | 0.81 | MAPT (0.46) | MAPTNPC1RAB9APSMB8SMN1; SMN2 | |
| SCHEMBL10480315 | 0.81 | MAPT (0.46) | MAPTNPC1RAB9APSMB8SMN1; SMN2 | |
| SCHEMBL2123396 | 0.81 | MAPT (0.50) | MAPTNPC1RAB9APSMB8SMN1; SMN2 | |
| SCHEMBL14600587 | 0.79 | MAPT (0.44) | MAPTNPC1RAB9APSMB8SMN1; SMN2 | |
| SCHEMBL12915263 | 0.78 | MAPT (0.47) | MAPTNPC1RAB9APSMB8SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12195469-B2 | Compounds having PDE9A inhibitory activity, and pharmaceutical uses thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-01-14 | — | — | US | disclosed |
| EP-3892623-B1 | COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF | KOREA RES INST CHEMICAL TECH (KR) | 2024-07-10 | — | — | EP | disclosed |
| CN-113166161-B | Compounds having PDE9A inhibiting activity and pharmaceutical uses thereof | 韩国化学研究院 | 2023-10-27 | — | — | CN | disclosed |
| US-20220024932-A1 | COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2022-01-27 | — | — | US | disclosed |
| US-20220024932-A1 | COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2022-01-27 | — | — | US | disclosed |
| US-11198687-B2 | Heteroaryl allosteric modulators of nicotinic acetylcholine receptors | MERCK SHARP & DOHME CORP. (US) | 2021-12-14 | — | — | US | disclosed |
| EP-3892623-A1 | COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF | Korea Research Institute of Chemical Technology (KR) | 2021-10-13 | — | — | EP | disclosed |
| CN-113166161-A | Compound with PDE9A inhibitory activity and pharmaceutical use thereof | 韩国化学研究院 | 2021-07-23 | — | — | CN | disclosed |
| US-20210135119-A1 | COMPOSITION OF MATTER FOR USE IN ORGANIC LIGHT-EMITTING DIODES | KYULUX, INC. (JP) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11198687-B2 | Heteroaryl allosteric modulators of nicotinic acetylcholine receptors | CHRNA7, CHRNA5, CHRNA2 | MAPT 425/4885NPC1 3457/4885RAB9A 489/4885 |
| US-12195469-B2 | Compounds having PDE9A inhibitory activity, and pharmaceutical uses thereof | PDE9A, PDE5A, PDE3A | MAPT 3479/4885NPC1 1359/4885RAB9A 38/4885 |
| US-20220024932-A1 | COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF | PDE9A, PDE5A, PDE3A | MAPT 3479/4885NPC1 1359/4885RAB9A 38/4885 |
| US-20210135119-A1 | COMPOSITION OF MATTER FOR USE IN ORGANIC LIGHT-EMITTING DIODES | CRY2, SLCO1B3, NDUFV3 | MAPT 112/4885NPC1 684/4885RAB9A 3734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.